🇺🇸 FDA
Patent

US 8557245

Methods for treating bone cancer by administering a nerve growth factor antagonist antibody

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 8557245 (Methods for treating bone cancer by administering a nerve growth factor antagonist antibody) held by Regents of the University of Minnesota expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K39/3955, A61P, A61P11/00